We therefore investigated the impact of CTLA-4 and PD-1 blockade on the selection of developing autoreactive B cells in both cancer patients and humanized mice injected with anti–CTLA-4 and anti–PD-1 mAbs. The gene discussed is CTLA4; the disease is cancer.